ITOS Live signaler | Maksimer profitt med Getagraph.com

SELG 107565 min ago

@ $10.28

Utstedt: 14 feb 2024 @ 15:30

Avkastning: 5.06%

Forrige signal: feb 12 - 21:25

Forrige signal: Kjøp

Avkastning: -3.95 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients...

Stats
Dagens volum	135 657
Gjennomsnittsvolum	277 176
Markedsverdi	387.11M
EPS	$0 ( 2024-03-20 )
Neste inntjeningsdato	( $-1.020 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.43
ATR14	$0.0140 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-07	Gall Matthew	Buy	163 200	Stock Option (Right to Buy)
2024-03-07	Call Matthew	Buy	225 000	Stock Option (Right to Buy)
2024-03-07	Mcgrath Yvonne	Buy	153 600	Stock Option (Right to Buy)
2024-03-07	Detheux Michel	Buy	590 400	Stock Option (Right to Buy)
2024-03-07	Desimone Jill	Buy	44 766	Stock Option (Right to Buy)

INSIDER POWER
64.45
Last 98 transactions
Buy: 4 056 310 \| Sell: 3 240 538

Volum Korrelasjon

Lang: -0.05 (neutral)

Kort: 0.71 (moderate)

Signal:(45.154) Neutral

iTeos Therapeutics, Inc. Korrelasjon

10 Mest positive korrelasjoner
VERU	0.964
AADI	0.945
MDRX	0.944
TWST	0.941
SGMO	0.941
LSBK	0.939
BLNK	0.936
ACRS	0.936
AKTX	0.936
ALHC	0.936

10 Mest negative korrelasjoner
CPTA	-0.934
RAM	-0.928
SGEN	-0.924
TYHT	-0.916
GPACU	-0.906
DRNA	-0.902
PESI	-0.897
XPON	-0.891
AMPH	-0.886
MLAI	-0.886

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

iTeos Therapeutics, Inc. Korrelasjon - Valuta/Råvare

-0.20
( neutral )

-0.12
( neutral )

0.00
( neutral )

0.04
( neutral )

iTeos Therapeutics, Inc. Økonomi

Annual	2023
Omsetning:	$12.60M
Bruttogevinst:	$11.70M (92.87 %)
EPS:	$-3.15

FY	2023
Omsetning:	$12.60M
Bruttogevinst:	$11.70M (92.87 %)
EPS:	$-3.15

FY	2022
Omsetning:	$267.63M
Bruttogevinst:	$266.82M (99.70 %)
EPS:	$2.72

FY	2021
Omsetning:	$344 775
Bruttogevinst:	$344 775 (100.00 %)
EPS:	$0.00881

Financial Reports:

No articles found.

iTeos Therapeutics, Inc.

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.